Thymosin Alpha 1: Evidence, Safety and Legal Status

24 minutes ago

8 min read

Unlabeled medicine vial and syringe on teal tray

Thymosin alpha 1 (Tα1, also called thymalfasin) is a 28-amino-acid peptide first isolated from the thymus gland. It modulates immune signaling, and it is an approved prescription medicine in some countries, mainly for chronic hepatitis B. In the United States it is not FDA-approved for any use. Its evidence is strongest in specific, serious conditions and weakest where it is most often marketed: general immune “boosting” and anti-aging in healthy people.

This guide covers what the peptide is, what the research shows, the side effects, who should not use it, the dosing you will see online and why it differs from the clinical protocols, and what the US regulatory picture means for you as a patient.

TL;DR

Thymosin alpha 1 is an immune-modulating peptide. It is approved abroad as Zadaxin, mainly for chronic hepatitis B, but it is not FDA-approved in the US.
Its effect depends on context. It helps restore function in exhausted immune systems, and there is little reason to expect a benefit in a healthy person.
Common side effects are injection-site redness, itching or soreness. Anyone with an autoimmune disease or on immunosuppressants needs medical review first.
A large 2025 sepsis trial found no overall survival benefit, so claims that it is a proven cure-all do not hold up.
Ask any provider where the product comes from. Source and quality matter as much as the dose.

What thymosin alpha 1 is and how it works
What the research shows
Side effects and safety
Dosing: clinical protocols versus wellness protocols
Is thymosin alpha 1 legal in the US?
How to evaluate a provider
Our perspective at Green Circle
When a clinic visit makes sense
FAQ
Sources

What thymosin alpha 1 is and how it works

The thymus is where T cells mature. Thymosin alpha 1 was first described as a thymic peptide, and a comprehensive literature review describes it as a naturally occurring peptide long recognized for modifying, enhancing and restoring immune function. The medicine used in trials is a synthetic version, thymalfasin.

The mechanism is immune modulation, not blanket stimulation. It promotes T-cell maturation and upregulates interferon-gamma signaling, according to a practitioner guide. The same source describes its best-supported role as immune restoration, meaning correcting an immune system that has become exhausted or “paralyzed” after severe illness.

That distinction matters for how you read marketing. A review of the evidence notes that the peptide’s effect is context-dependent. In an exhausted immune system it can help restore balance. In a healthy person there is no dysfunction to correct, so a clear benefit from “preventive” use is unlikely.

What the research shows

Chronic hepatitis B and C

This is the core of the approval abroad. Thymalfasin is a licensed medicine in countries including China and Italy, principally for chronic hepatitis B. For hepatitis C, the literature review above reports trials of thymosin alpha 1 combined with interferon alpha, with a meta-analysis favoring the combination over interferon alone. Those were older antiviral regimens, and hepatitis C treatment has changed a great deal since. Treat the data as historical context, not a reason to seek the peptide today.

Sepsis

Earlier smaller studies suggested a survival benefit, but they were limited by sample size and study quality, as a systematic review of randomized trials noted. A large 2025 phase 3 randomized, double-blind trial of 1,106 adults with sepsis then found no overall mortality benefit: 23.4% mortality with thymosin alpha 1 versus 24.1% with placebo. The same source suggests the peptide may be best viewed as a niche option for specific immunoparalysis states, not a general therapy.

COVID-19

Tα1 was widely used in some countries during the pandemic. A systematic review and meta-analysis in adults with COVID-19 opens by stating that its effect remains unclear. That is the honest summary: widespread use did not equal proof.

Healthy people, longevity and weight loss

People also ask whether it helps with weight loss or aging. We found no controlled trial evidence supporting thymosin alpha 1 for weight loss, and the research above gives no basis for expecting a longevity benefit in healthy adults. If a provider promises either, ask to see the trial. For a closer look at what has and has not been demonstrated, see our review of thymosin alpha 1 benefits and when they matter.

Side effects and safety

The research describes thymosin alpha 1 as generally well tolerated. The usual side effects are local:

Redness at the injection site
Itching
Soreness or mild irritation

The literature review lists local irritation as the most common effect. In trials where it was combined with interferon, rarer events such as fever, fatigue, muscle aches, nausea and vomiting were reported, and the review lists hypersensitivity to the peptide as a contraindication. Treat any hives, facial swelling or trouble breathing after an injection as an emergency and call 911.

In hepatitis B patients, clinicians sometimes see a temporary rise in liver enzymes (an ALT flare). According to Singapore’s product information, clinicians generally read this as the immune system engaging the virus rather than drug-induced liver failure. That interpretation belongs to a physician monitoring liver tests, not to someone self-injecting. If you are injecting at home, our guide to injection-site reactions on GLP-1 medicines covers what is typically mild and what warrants a call to your clinician, and much of it applies to any subcutaneous injection.

Who should not use it

This is the part most online content skips. Because the peptide enhances T-cell function, practitioners consider it a poor fit, or contraindicated, in several groups:

People with autoimmune disease. An immune enhancer can theoretically trigger or worsen a flare, as practitioner guidance points out.
People on deliberate immunosuppression, such as transplant maintenance therapy or potent drugs for lupus or rheumatoid arthritis. The goal of those drugs is the opposite of what the peptide does.
Anyone with a known hypersensitivity to thymosin alpha 1.

Pregnancy and breastfeeding data are not established in the sources we reviewed, so those patients should not use it without a physician’s direction. If you have an autoimmune condition and have been told peptides can “balance” your immune system, bring that claim to your rheumatologist or immunologist before any injection.

Dosing: clinical protocols versus wellness protocols

Where the pharmaceutical product is approved, the standard regimen is 1.6 mg given subcutaneously twice weekly for 6 to 12 months, usually for chronic hepatitis B. Online “wellness” protocols often copy the 1.6 mg figure. Some guides describe doses of 1.6 mg to 3.2 mg per week, but the protocols found online often lack controlled-trial backing, and cycle lengths vary widely.

A useful rule: the dose from a trial applies to the product used in that trial, for the condition studied, in the patients enrolled. It does not transfer to a different product, a different purpose or a healthy person.

Question	Pharmaceutical use abroad	Typical online wellness use
Product	Pharmaceutical-grade thymalfasin (Zadaxin)	Compounded, imported or “research” peptide
Purpose	Chronic hepatitis B, mainly	General immunity, longevity
Dose	1.6 mg twice weekly	Varies widely
Duration	6 to 12 months	Often undefined
Oversight	Regulator-approved manufacturing	Often none

Is thymosin alpha 1 legal in the US?

It is not FDA-approved for any medical use. The FDA’s page on bulk drug substances used in compounding under section 503A says that state-licensed physicians and pharmacists may compound only with bulk substances that meet specific criteria, and thymosin alpha 1 is not on the 503A bulks list. Tα1-related substances were nominated for that list, and the FDA’s advisory committee discussed them in December 2024, but a nomination or discussion is not an approval.

The status has shifted before. The FDA keeps a separate page on bulk substances that may present significant safety risks, and the categories there have been revised. Check the FDA pages directly for the current position before you act on anything you read, including this article.

Three practical consequences:

Be wary of “FDA-approved” claims. Any clinic describing thymosin alpha 1 as an FDA-approved treatment is wrong.
Approval abroad does not validate what is sold here. Compounded or online-bought peptide lacks the standardized manufacturing and purity testing of the pharmaceutical-grade product used in the trials that built the efficacy record.
Ask about the source. A responsible provider can tell you who made the product, how purity is verified and what the regulatory status is, without hedging.

How to evaluate a provider

Before you consider any thymosin alpha 1 protocol, ask these questions:

What is my specific immune problem, and which test shows it?
What does the trial evidence say for people like me, not for hepatitis B or sepsis patients?
Where does the product come from, and can you document its quality?
How will you monitor me, and what would make us stop?
What are the alternatives, including doing nothing new?

If the answers are vague, or the pitch is the same for every patient, keep looking.

Our perspective at Green Circle

We see many patients who arrive asking for a peptide they read about, and thymosin alpha 1 is a frequent one. Our job is to start with the person, not the product. That means asking what is going on underneath: recurrent infections, long recovery after illness, fatigue, an autoimmune diagnosis, or a general wish to stay well. Those are very different situations, and the same peptide does not answer them.

Our view is shaped by the evidence above. The peptide is a targeted immunomodulator with a real record in a narrow set of conditions, and a thin record elsewhere. It is not a longevity shortcut. For a patient with an autoimmune condition, the first question is whether it could do harm. For a healthy patient, the better investments are usually sleep, nutrition, vaccination, stress, hormone and gut health, and testing to find real gaps.

That is why we spend time on history, labs and biomarkers before discussing any therapy, and why we are open about regulatory gray areas. A peptide that is not FDA-approved, or not legally compounded, should be discussed plainly, not sold on enthusiasm. We have taken the same careful approach to other peptides, such as AOD-9604 and peptides marketed for sleep.

— Dina

When a clinic visit makes sense

If you are weighing thymosin alpha 1 because of frequent infections, slow recovery, or an immune or autoimmune question, an evaluation is a better first step than a purchase. Our functional medicine team takes the time to review your history and testing, and our peptide therapy page explains how we approach peptides in general. You can read more about how we work, or see all our services. We serve patients in Chicago and offer virtual consults for Illinois residents.

FAQ

What are the side effects of thymosin alpha 1?

The most common are local: redness, itching or soreness where the injection was given. Less often, studies combining it with other drugs reported fever, fatigue, muscle aches or nausea. Hepatitis B patients may see a temporary liver enzyme rise that their physician monitors. Allergic reactions are possible, and swelling or trouble breathing needs emergency care.

Who should not take thymosin alpha 1?

People with known hypersensitivity to it, people with autoimmune disease and people taking immunosuppressants, such as transplant recipients or patients with lupus or rheumatoid arthritis, should not use it without specialist approval. It stimulates T-cell activity, which may worsen autoimmune flares or work against immunosuppressive treatment.

How long should you take thymosin alpha 1?

There is no validated wellness protocol. In countries where the medicine is approved, treatment for chronic hepatitis B has typically run 6 to 12 months at 1.6 mg twice weekly under medical supervision. Durations promoted online for healthy people are not backed by controlled trials.

Can thymosin alpha 1 help with weight loss?

We found no controlled evidence that it does. It is an immune modulator, not a metabolic drug. If weight loss is your goal, a medical evaluation of nutrition, hormones, sleep and metabolic health will do more for you.